Cross-reactivity of the CEDIA buprenorphine assay with opiates: an Austrian phenomenon?

Pavlic,M.; Libiseller,K.; Grubwieser,P.; Rabl,W.
When testing the Microgenics CEDIA assay for immunological buprenorphine analysis, cross-reactivity between the buprenorphine reagents and opiates was observed at concentrations higher than 120 mg/l morphine, 320 mg/l methadone, 30 mg/l codeine, 60 mg/l dihydrocodeine and 520 mg/l morphine-3-glucuronide. The cross-reactivity with morphine has the greatest impact on routine screening as opiate maintenance therapy in Austria is also performed with slow-release oral morphine. The use of a second cutoff value of 30 mug/l for urine samples that are (immunologically) positive for opiates is therefore suggested, compared to the cutoff value of 5 microg/l proposed by the manufacturer
Int J Legal Med 2005 119(6):378-381
Tags: Austria; Buprenorphine; Cross Reactions; human; Immunoassay; immunology; impact; Linear Models; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; rehabilitation; Retrospective Studies; therapeutic use; therapy; urine
PubMed: 15834736
Home » Research » Publications » Detail